Fecal Occult Testing Products Market Size, Share, Industry, Forecast and outlook (2024-2031)

Fecal Occult Testing Products Market is segmented By Product ( Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test), By End-User ( Hospitals, Clinical Diagnostic Laboratories, Physician’s Office Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Fecal Occult Testing Products Market Overview

Fecal occult testing products market is estimated to reach at a CAGR 5.7% during the forecast period 2023-2030. 170 pages report analyses the Fecal occult testing products market shares, recent trends, competitive intelligence and future market outlook. Fecal occult testing products usage in diagnostic screening test is on the rise. Demand from pharmaceuticals & commercial infrastructurein ‘North America’ is booming. Competitive rivalry intensifies with LifeSign PBM, Ameritek, Inc., Immunostics Inc., Biomerica and others operating in the market.

FOBT stands for the fecal occult blood test, and it is a diagnostic screening test that looks for hidden (occult) blood in stool samples. These tests detect polyps in the colon or rectum and polyps that bleed, screen for colon cancer, and determine the origin of unexplained anemia.

Fecal Occult Testing Products Market Summary

Fecal Occult Testing Products Market Dynamics

The increasing adoption rate of point-of-care testing products is expected to drive the growth of the market

POCT is perceived as a broader spectrum of technologies, settings (hospitals, homes, clinics, communities and peripheral laboratories), and users (highly trained to a layperson). It is a clinical diagnostic laboratory testing designed to be used at the point in time, performed at or near the clinical laboratory site. It could be enclosed near the patient and receiving treatment care. The testing and care are typically conducted by clinical personal or self-testing by the patients themselves. Point of care testing is otherwise defined as any testing performed bedside, near-patient, outside of the conventional, core, or central laboratory usually performed by non-laboratory staff. The outcomes are utilized for clinical decision-making. Their major aims are to generate quick results so that suitable treatment can be executed, enhancing clinical and economic outcomes.

Moreover, multiple areas of expertise, various elements, and testing need are combined to introduce as a part of POCT, which includes rapid communication of assessment results between patients and care providers, to ensure proper follow-up of patients and a system for fast-track initiation of treatments. Therefore, the above statements have increased the adoption of point-of-care testing products, which is expected to drive the market's growth.

Drawbacks associated with the at-home fecal occult blood testing products are expected to hamper the market growth.

According to the American Cancer Society and the American Gastroenterological Association, anyone aged 50 and up who has a normal risk of having colon cancer should be checked for it. There are various products available for at-home testing for blood in the stool. The usual method has been to use a stool card and place a stool sample in the testing area. There are toilet bowl tests, for example, that do not require any stool handling. Cleaning chemicals and toilet bowl fresheners may disrupt the test. The test kits include control pads for testing the conditions in the toilet bowl and pads that are placed within the toilet bowl. It is done to boost the accuracy by testing three consecutive bowel movements. If the patients consume more than 250 milligrams of vitamin C during the test, false-negative findings may arise. As a result, at-home fecal occult blood testing products do not provide accurate results, and the market is expected to decline during the forecast period.

Fecal Occult Testing Products Market Industry Analysis

PEST Analysis:   

COVID-19 Impact Analysis

The pandemic caused by the SARS-CoV-2 virus led to a near-worldwide lockdown and has moderately impacted the manufacturing of fecal occult testing products. The pandemic affected the prevention, diagnosis and treatment of cancer. It has resulted in increased cancer and late diagnosis and mortality with a higher overall economic cost. Moreover, the prioritization of COVID-19 and implementation of a physical distancing and intervention strategy has hampered the ability of cancer health providers to function, specifically by delaying cancer screening, in-person consultations, and control tests, as well as limiting treatments that resulted in serious infectious complications.

Additionally, according to the American Society of Clinical Oncology, almost two-thirds of people supposed to have cancer tests during the epidemic missed or delayed them.) Although at-home fecal occult blood tests, such as FIT, are a good option for most people who are worried about obtaining a screening colonoscopy at this time, some past studies have raised tions from health officials and professional organizations, routine screening, follow-up and monitoring activity have diminished significantly for the last two months, and even some labs have limited the amount of staff working at one time, even adjusting their shift schedules to ensure groups do not inadvertently spread the infection. Thus, the situation is expected to improve gradually in the forecast period.

Fecal Occult Testing Products Market Segment Analysis

Guaiac FOB Stool Test segment is expected to hold the largest market share in this market segment.

The guaiac FOB stool test segment held the largest market share in 2020. Screening for colorectal cancer (CRC) by fecal occult blood testing (FOBT) has effectively reduced CRC mortality and incidence and is recommended in several countries as current health policy. The guaiac fecal occult blood test (FOBT) detects occult blood in the stool (blood that cannot be seen with the naked eye). The theory behind this test is that blood veins on the surface of bigger polyps or tumors are frequently weak and easily broken by passing stool. A tiny quantity of blood is frequently released into the stool by the ruptured blood vessels, although there is rarely enough bleeding visible in the stool. The FOBT is a simple test that tells the patient has blood in their stool caused by polyps or colorectal cancer. 

Moreover, this screening test is performed using a kit that you can use in comfort at home. Another significant aspect of this kit and test is that it requires examining more than one stool sample. In addition, unlike several other screening procedures (including colonoscopy), the test is repeated every year and is inexpensive and straightforward to perform. As a result of the preceding assertions, demand for the guaiac FOB test has surged, and it is predicted to hold the greatest market share during the forecast period.

Fecal Occult Testing Products Market Geographical Analysis

North America region holds the largest market share in the global fecal occult testing products market.

North America accounted for the largest market share in 2020. The rising prevalence of colon cancer, extensive public awareness, increased demand for technologically sophisticated fecal occult blood test kits, the adoption rate of point-of-care testing devices, and product releases by key players all contribute to the region's growth over the forecast period. According to the American Cancer Society, colorectal cancer is the third most common cancer discovered in men and women in the United States. In the United States, colorectal cancer cases are anticipated to rise by 104,270 new cases of colon cancer and 45,230 new cases of rectal cancer in 2021. Moreover, men have a 1 in 23 (4.3%) lifetime risk of having colorectal cancer, while women have a 1 in 25 (4.0%) lifetime risk.

Additionally, on August 5, 2021, Biomerica launched its new website for its EZ DetectTM Colon Disease Test product at https://ezdetect.com. The site has been designed with streamlined functionality and simple access to vital and potentially life-saving information about the detection and treatment of colorectal disorders, such as colon cancer. Therefore, the need for fecal occult testing kits has surged. Thus, North America is predicted to have the largest market share during the forecast period.

Fecal Occult Testing Products Market Competitive Landscape

The fecal occult testing products market is vast with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include LifeSign PBM, Ameritek, Inc., Immunostics Inc., Biomerica, Sentinel Ch., RTA Laboratories, Labtest Diagnostica, PRIMA Lab, Eurolyser Diagnostica and Diagnosis. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the fecal occult testing products market globally.

Fecal Occult Testing Products Market Key Companies to Watch

Immunostics Inc.:

Overview:

Immunostics is a private company established in 1983 is a leading provider of high-quality microbiological, serological and immuno- logical diagnostic kits and reagents. The company products are focused on oncology, women's health, infectious disease, respiratory and toxicology. Moreover, it offers a wide range of rapid immunoassays, including Fecal Occult Blood, Strep A, Pregnancy, Mono, and H. Pylori, Urine Reagent Strips and a Portable Bench Top Analyzer for semi-quantitative and qualitative determination of various parameters.

Product Portfolio:

Immunostics Inc. is manufacturing Fecal Occult Testing Products products, including Rapid fecal occult blood test hema-screen HS-50, HS-100, HS-1000.